NL300270I1 - Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin met uiteengevallen en weer samengestelde virusachtige deeltjes. - Google Patents

Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin met uiteengevallen en weer samengestelde virusachtige deeltjes.

Info

Publication number
NL300270I1
NL300270I1 NL300270C NL300270C NL300270I1 NL 300270 I1 NL300270 I1 NL 300270I1 NL 300270 C NL300270 C NL 300270C NL 300270 C NL300270 C NL 300270C NL 300270 I1 NL300270 I1 NL 300270I1
Authority
NL
Netherlands
Prior art keywords
disintegrated
particles
preparation
human papillomavirus
papillomavirus vaccine
Prior art date
Application number
NL300270C
Other languages
English (en)
Dutch (nl)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26824774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300270(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NL300270I1 publication Critical patent/NL300270I1/nl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/10Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NL300270C 1999-03-26 2007-03-13 Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin met uiteengevallen en weer samengestelde virusachtige deeltjes. NL300270I1 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12652899P 1999-03-26 1999-03-26
US09/524,624 US6245568B1 (en) 1999-03-26 2000-03-13 Human papilloma virus vaccine with disassembled and reassembled virus-like particles
PCT/US2000/007595 WO2000057906A1 (en) 1999-03-26 2000-03-22 Human papillomavirus vaccine with disassembled and reassembled virus-like particles

Publications (1)

Publication Number Publication Date
NL300270I1 true NL300270I1 (nl) 2007-05-01

Family

ID=26824774

Family Applications (3)

Application Number Title Priority Date Filing Date
NL300270C NL300270I1 (nl) 1999-03-26 2007-03-13 Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin met uiteengevallen en weer samengestelde virusachtige deeltjes.
NL300269C NL300269I2 (nl) 1999-03-26 2007-03-13 Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin
NL300268C NL300268I1 (nl) 1999-03-26 2007-03-13 Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin met uiteengevallen en weer samengestelde virusachtige deeltjes.

Family Applications After (2)

Application Number Title Priority Date Filing Date
NL300269C NL300269I2 (nl) 1999-03-26 2007-03-13 Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin
NL300268C NL300268I1 (nl) 1999-03-26 2007-03-13 Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin met uiteengevallen en weer samengestelde virusachtige deeltjes.

Country Status (19)

Country Link
US (2) US6245568B1 (https=)
EP (1) EP1165126B1 (https=)
JP (1) JP4594534B2 (https=)
KR (1) KR20020013516A (https=)
AR (1) AR023166A1 (https=)
AT (1) ATE339222T1 (https=)
AU (1) AU778937B2 (https=)
CA (1) CA2368391C (https=)
CY (4) CY1105779T1 (https=)
DE (4) DE122007000033I1 (https=)
DK (1) DK1165126T3 (https=)
ES (1) ES2270822T3 (https=)
FR (1) FR07C0026I2 (https=)
LT (1) LTC1165126I2 (https=)
LU (3) LU91327I2 (https=)
NL (3) NL300270I1 (https=)
PT (1) PT1165126E (https=)
SI (1) SI1165126T1 (https=)
WO (1) WO2000057906A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962777B1 (en) * 1997-09-05 2005-11-08 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
US7351533B2 (en) 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
CA2875298A1 (en) * 1999-12-09 2001-06-14 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps)
RU2323002C2 (ru) * 2001-07-26 2008-04-27 Чирон Срл. Вакцины, содержащие алюминиевые адъюванты и гистидин
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
US20060073530A1 (en) * 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US20040121465A1 (en) * 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DE10237639A1 (de) * 2002-08-13 2004-02-26 Martin-Luther-Universität Halle-Wittenberg Verfahren zur Herstellung von virusanalogen Partikeln durch in vitro-Assemblierung von Kapsomeren oder von Kapsomeren, an die biologisch aktive Makromoleküle gebunden sind, bei gleichzeitiger Verpackung der Makromoleküle
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CA2503946C (en) 2002-11-01 2016-08-16 Glaxosmithkline Biologicals S.A. Drying process
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
PT1572233E (pt) 2002-12-20 2011-06-07 Glaxosmithkline Biolog Sa Utilização de hpv16 e hpv18 como vacina contra um ou mais de tipos de hpv oncogénicos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
US20080131928A1 (en) * 2004-07-01 2008-06-05 Hiroshi Handa Viral Particle-Like Construct and Method of Forming the Same Under Physiological Conditions
GT200600027A (es) * 2005-01-25 2006-08-31 Protectores contra el esfuerzo cortante en la microfiltracion de la cosecha
US7759104B2 (en) * 2005-07-14 2010-07-20 Mayo Foundation For Medical Education And Research Paramyxoviridae virus preparations
EP1920779A4 (en) * 2005-08-12 2010-03-10 Astellas Pharma Inc YW753 PREPARATION STABILIZATION TECHNIQUE
US20080268000A1 (en) * 2005-09-01 2008-10-30 Jose Luis Nuno Ayala Vaccine Stabilising Formula with Live Antigens for Use in Mass Vaccination Systems
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
JP2009536958A (ja) * 2006-05-11 2009-10-22 ベクトン・ディキンソン・アンド・カンパニー 細胞からのタンパク質抽出方法
US9207240B2 (en) * 2007-11-14 2015-12-08 Arbor Vita Corporation Method of efficient extraction of protein from cells
JP5313231B2 (ja) * 2008-03-31 2013-10-09 森永乳業株式会社 耐熱性を付与する薬剤及び組成物
EP2473596B1 (en) * 2009-09-03 2017-12-13 Becton, Dickinson and Company Methods and compositions for direct chemical lysis
CN107913396B (zh) 2010-08-23 2022-03-08 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
WO2013139744A1 (en) 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Method of vaccination against human papillomavirus
KR101559622B1 (ko) * 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2018152505A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Efficient cell free production of papillomavirus gene transfer vectors
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN110987571A (zh) * 2019-12-31 2020-04-10 广州金域医学检验中心有限公司 一种单克隆多聚体m蛋白解聚方法
CN111812313B (zh) * 2020-06-22 2021-10-08 北京生物制品研究所有限责任公司 铝佐剂吸附型新型冠状病毒灭活疫苗中抗原的解离方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034594A1 (en) * 1997-02-06 1998-08-13 Merck & Co., Inc. Thimerosal-free preservatives for vaccines
PT973546E (pt) 1997-04-08 2004-06-30 Merck & Co Inc Formulacoes estabilizadas de virus de papiloma humano
CA2295316C (en) 1997-07-03 2007-06-26 University Of Colorado, University Technology Corporation Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy

Also Published As

Publication number Publication date
NL300268I1 (nl) 2007-05-01
US6245568B1 (en) 2001-06-12
FR07C0026I2 (fr) 2012-08-03
CY2007009I1 (el) 2010-07-28
FR07C0026I1 (https=) 2007-04-27
CA2368391A1 (en) 2000-10-05
CY2007008I2 (el) 2009-11-04
AU3909300A (en) 2000-10-16
CY2007008I1 (el) 2009-11-04
SI1165126T1 (sl) 2006-12-31
DK1165126T3 (da) 2007-01-08
LU91326I9 (https=) 2018-12-31
LTPA2007002I1 (lt) 2020-03-25
AU778937B2 (en) 2004-12-23
CY2007009I2 (el) 2010-07-28
NL300269I1 (nl) 2007-05-01
LU91327I9 (https=) 2019-03-01
LU91328I9 (https=) 2019-03-01
JP2002540167A (ja) 2002-11-26
EP1165126B1 (en) 2006-09-13
PT1165126E (pt) 2006-12-29
DE60030698D1 (de) 2006-10-26
LU91327I2 (fr) 2007-05-14
WO2000057906A1 (en) 2000-10-05
JP4594534B2 (ja) 2010-12-08
LU91326I2 (fr) 2007-05-14
DE60030698T2 (de) 2007-07-19
LU91328I2 (fr) 2007-05-14
US20010021385A1 (en) 2001-09-13
DE122007000034I1 (de) 2007-08-09
CA2368391C (en) 2011-06-07
ES2270822T3 (es) 2007-04-16
LTC1165126I2 (lt) 2020-04-27
DE122007000033I1 (de) 2007-08-09
DE122007000032I1 (de) 2007-08-09
KR20020013516A (ko) 2002-02-20
EP1165126A1 (en) 2002-01-02
NL300269I2 (nl) 2008-07-01
CY2007010I1 (el) 2009-11-04
ATE339222T1 (de) 2006-10-15
CY1105779T1 (el) 2010-07-28
CY2007010I2 (el) 2009-11-04
AR023166A1 (es) 2002-09-04

Similar Documents

Publication Publication Date Title
NL300269I1 (nl) Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin met uiteengevallen en weer samengestelde virusachtige deeltjes.
EE04991B1 (et) Osake, ravimvorm, nende valmistamismeetodid, osakeste kasutamine ning farmatseutiline pakend
AU2003235707A8 (en) Immunogenic preparations and vaccines on the basis of mrna
AU2003227533A8 (en) Virus like particle from papillomavirus and their use in vaccine
AU2002241534A1 (en) Disposable aerosol generator system and methods for administering the aerosol
IL163814A0 (en) Virus-like particles of human papillomavirus
PL409839A1 (pl) Ludzkie przeciwciała, które wiążą ludzką IL-12 i sposoby ich wytwarzania
PL349425A1 (en) Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament
AU2002220151A1 (en) Method and system for the detection of heart disease
EP1322326A4 (en) VACCINES DIRECTED TO THE INNE IMMUNE SYSTEM
AU2003271021A1 (en) Immunogen for preparation of therapeutic vaccines or drugs for treatment of hepatitis b and the producing method and use thereof
AU2001266392A1 (en) The controlled release preparation of insulin and its method
PL373328A1 (en) Sustained release pharmaceutical prepartations and methods for producing the same
NL1032282A1 (nl) N-terminaal monogepegyleerde conjugaten van humaan groeihormoon en werkwijze voor de bereiding daarvan.
EP1543841A4 (en) SOLID PHARMACEUTICAL NANO FORMULATION AND MANUFACTURING METHOD THEREFOR
AU2001269640A1 (en) Vaccine against the influenza virus and method for producing said virus vaccine
AU6964001A (en) Vaccine against the influenza virus and method for producing said virus vaccine
AU2003290012A1 (en) L2-peptide of the human papillomavirus associated with virus-like particles
AU2003278175A1 (en) Vaccines of enhanced immunogenicity, and methods for preparing such vaccines
IL169124A0 (en) Preparation and administration of hybrid cell vaccines for the prevention of cancer
AU2001248839A1 (en) Remedies for interstitial pneumonia, method of constructing animal model of this disease and screening method with the use of the same
AU2273301A (en) Methods and formulations for the efficient delivery of water-insoluble drugs by nebulizer
WO2004058816A3 (en) Inclusion bodies for the oral vaccination of animals
AU2001294880A1 (en) Non-replicative particulate vaccine delivery system and methods of making and using same
ZA200410137B (en) Chimaeric human papillomavirus 16 L1 virus like particles and a method for preparing the particles.